研究论文

镍(II)/双咪唑啉催化不对称高阶(5+3)环化反应构建兼具中心与轴手性的马鞍形八元桥联联芳基衍生物

  • 陈颂耀 a ,
  • 冯雪 a ,
  • 屠蔓苏 , b, * ,
  • 郝文娟 a ,
  • 姜波 , a, *
展开
  • a 江苏师范大学化学与材料科学学院 江苏徐州 221116
  • b 江苏师范大学科技园有限公司 江苏徐州 221116

收稿日期: 2025-02-14

  修回日期: 2026-03-07

  网络出版日期: 2026-03-27

基金资助

国家自然科学基金(22271123)

江苏省基础研究计划(BK20230201)

江苏省基础研究计划(BK20251927)

Ni(II)/Bisimidazoline-Catalyzed Asymmetric Higher-Order (5+3) Annulation for the Construction of Saddle-Shaped Eight-Membered Bridged Biaryls with Concurrent Central and Axial Chirality

  • Song-Yao Chen a ,
  • Xue Feng a ,
  • Man-Su Tu , b, * ,
  • Wen-Juan Hao a ,
  • Bo Jiang , a, *
Expand
  • a School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou, Jiangsu 221116
  • b Science and Technology Park Co., Ltd., Jiangsu Normal University, Xuzhou, Jiangsu 221116

Received date: 2025-02-14

  Revised date: 2026-03-07

  Online published: 2026-03-27

Supported by

National Natural Science Foundation of China(22271123)

Basic Research Program of Jiangsu Province(BK20230201)

Basic Research Program of Jiangsu Province(BK20251927)

Copyright

© 2026 Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

摘要

报道了一种2-(2-氨芳基)吲哚和β,γ-不饱和α-酮酯衍生物参与的新型不对称镍(II)/双咪唑啉配体催化高阶(5+3)增环反应, 高立体选择性地合成含有马鞍形八元环桥联联芳基结构的三环、四环吲哚衍生物, 产率中等至良好. 其中, 1-(2-吲哚基)萘-2-胺作为1,5-双亲核组分, 在标准反应条件下发生高阶(5+3)环化, 以高非对映选择性和对映选择性合成四环吲哚产物. 同时, N-保护2-(2-氨芳基)吲哚也可作为替代的1,5-双亲核试剂, 同样实现高效转化, 获得具有同等立体控制水平的三环吲哚衍生物. 该方法表现出良好官能团耐受性和广泛底物范围, 且反应条件温和, 为合成手性中环桥联联芳基化合物提供了一种稳健且可供选择的方法.

本文引用格式

陈颂耀 , 冯雪 , 屠蔓苏 , 郝文娟 , 姜波 . 镍(II)/双咪唑啉催化不对称高阶(5+3)环化反应构建兼具中心与轴手性的马鞍形八元桥联联芳基衍生物[J]. 有机化学, 2026 , 46(7) : 2796 -2807 . DOI: 10.6023/cjoc202602016

Abstract

A new Ni(II)/bisimidazoline (Bim)-catalyzed asymmetric higher-order (5+3) annulation of 2-(2-aminoaryl)indoles and β,γ-unsaturated α-ketoesters is reported, enabling stereoselective access to tri- and tetracyclic indoles containing a saddle-shaped eight-membered-ring bridged biaryl architecture in moderate to good yields. When subjected to the reaction conditions, 1-(2-indolyl)naphthalen-2-amines functioning as 1,5-dinucleophilic partners underwent efficient higher-order cyclization to afford tetracyclic indoles with high diastereo- and enantioselectivity. In parallel, N-protected 2-(2-aminophenyl)indoles effectively served as alternative 1,5-dinucleophiles, delivering tricyclic indoles with comparable stereocontrol. The present protocol demonstrates good functional group tolerance, a broad substrate scope and mild reaction conditions, thereby providing a robust and alternative approach to accessing chiral medium-sized bridged biaryls.

1 Introduction

Axially chiral biaryl architectures are abundant in a wide assortment of natural products,[1] and biologically active molecules[2], some of which constitute the core structures of privileged chiral ligands or organocatalysts for asymmetric transformations.[3] In line with these contributions, the catalytic enantioselective construction of chiral biaryl scaffolds has evolved into a stimulating topic in synthetic science. In terms of structural characteristics, conformationally stable biaryl atropisomers can generally be divided into the following two categories: noncyclic and bridged biaryls (Figure 1a). The former comprises conformers with a rotationally hindered stereogenic axis whose configurational stability is normally governed by the number and size of the flanking substituents close to the stereogenic axis because sufficient steric congestion could cause a high rotational energy barrier, making the axis chirality stable (ΔG>123.6 kJ/mol). The last decade has witnessed many significant achievements in this field, most of which focus on the enantioselective assembly of six-six- and five-six-membered biaryl atropisomers.[3-4] In the latter, bridged biaryl atropisomers, characterized by the covalent linkage of two ortho-substituents on adjacent aryl rings via a bridging unit (ΔG usually less than 123.6 kJ/mol), exhibit configurational stability that is critically governed by the ring size of the bridging ring.[5] Notably, five- and six-membered bridges generally afford insufficient steric congestion and conformational restrictions to hinder rotation around the biaryl axis due to the low rotational energy barrier.[6] In contrast, medium-sized bridges uniquely demonstrate flexibility and rigidity through the expansion of their geometric structures to decrease transannular strain while enhancing a well- defined stable conformation through favorable torsional and noncovalent interactions.[5-7] In particular, medium-sized bridged biaryl scaffolds are widely distributed in numerous natural products, such as (+)-isoschizandrin,[8b] (+)-stega- nacin[8b] and (-)-rhazinilam,[8c] and other bioactive molecules, with demonstrated therapeutic relevance (Figure 1b).[9] Notably, when the bridging linkage contains central chirality, its configuration can stereoselectively govern the axial stereochemistry through a well-established central-to- axial chirality relay event.[7] This phenomenon has been documented in recent studies on the asymmetric construction of eight-membered bridged biaryl scaffolds. An illustrative example is the N-heterocyclic carbene (NHC)-cata- lyzed propargylic substitution-enabling bicyclization of propargylic alcohols with enals, producing enantioenriched eight-membered lactones featuring an axially chiral aryl- indole bridge and a chiral carbon center, as reported by Wong and Zhao (Scheme 1a).[10] The subsequent NHC- catalyzed (5+3) annulation of ortho-indolizinyl N-sulfon- ylanilines with α-bromoenals afforded eight-membered lactams connecting an aryl-indolizine bridge and a chiral carbon center (Scheme 1b).[11] Despite these limited advances, synthesizing chiral medium-sized bridged biaryl atropisomers poses a great challenge and remains underdeveloped, because of unfavorable transannular interactions and entropic and/or enthalpic factors.[12] Thus, novel synthetic strategies are needed to access atropisomerically enriched 8-membered bridged biaryl systems while addressing the above issues.[13]
Figure 1 Types of axial chiral compounds and medium-sized bridged biaryl-containing natural products
Scheme 1 Profiles for asymmetric synthesis of eight-membered heterocycles
We recently developed a class of chiral C2-symmetric anionic N,N′-bidentate ligands, N,N′-disulfonyl bisimidazolines (Bims). Upon coordination to Pd(II), these ligands deliver highly enantioselective catalysis in both 1,2- and 1,4-conjugate addition reactions. This asymmetric ligand- enabled Pd(II) catalytic system provides reliable and efficient access to a broad range of optically pure cyclic α- tertiary amines and ketones.[14] To further broaden the asymmetric synthetic application of the preformed Bim ligand by extending its coordination to additional transition metals, we found that the Ni(II)/Bim catalytic system could drive higher-order (5+3) annulation of 2-(2-aminoaryl)- indoles and β,γ-unsaturated α-ketoesters,[15] affording saddle-shaped eight-membered aza-heterocycles featuring an axially chiral aryl-indole fragment with high enantioselectivity and excellent diastereoselectivity. When we were preparing this paper, Zhao and co-workers[16] reported an In(OTf)3/pybox-catalyzed (5+3) annulation for the enantioselective formation of similar eight-membered ring- bridged 2-aryl-indoles (Scheme 1c). A comparative analysis of the aforementioned literature reveals that the catalytic systems, reaction parameters, and substitution patterns of the products are all markedly distinct. Therefore, herein, we report the application of this Ni(II)/chiral Bim catalytic system to achieve higher-order (5+3) annulation for the diastereo- and enantioselective synthesis of saddle-shaped eight-membered aza-heterocycles.

2 Results and discussion

Our studies were started with the reaction of 1-(2-in- dolyl)naphthalen-2-amine (1a) and β,γ-unsaturated α-keto- ester (2a) as model substrates to optimize the reaction parameters (Table 1). The reaction of 1a with 2a was conducted in 1,2-dichloroethane (DCE) at room temperature under air conditions by using the Ni(NTf2)2/chiral Bim ligand L1, and the expected product 3a was obtained in 55% yield and 57% ee (Entry 1). These findings prompted a focused investigation into the influence of reaction parameters on both product yield and enantioselectivity. Subsequently, the influence of the solvents was carefully evaluated. The yields of product 3a obtained using the Ni(II)/L1 catalytic system in several solvents commonly employed in asymmetric transformations are summarized as follows (Entries 2~6): toluene (70%, 65% ee), acetonitrile (CH3CN, 21%, 32% ee), N,N-dimethylformamide (DMF, trace), tetrahydrofuran (THF, trace), and methyl tert-butyl ether (MTBE, 70%, 80% ee), in which the use of MTBE gave better results than MTBE did (Entry 1 vs Entry 6). Next, a series of chiral ligands, including N,N′-disulfonyl Bim L2~L10, benzo[d]imidazole L4, PyIPI L12~L14,[17] Pyrox L15, Box L16, and Pybox-L17 (Entries 7~22), were investigated, and the results indicated that all the ligands led to a significant decrease in the yield and/or enantioselectivity of the product. Exchanging Ni(NTf2) with Ni(OTf)2, or NiBr2 led to markedly diminished catalytic performance, as evidenced by the significantly decreased ee values of product 3a (Entries 23, 24). The use of Cu(OTf)2 or Zn(OTf)2 as a Lewis acid catalyst led to the poor enantioselectivity (Entries 25, 26).
Table 1 Condition optimization for product 3aa

Entry [M] L Solvent Yield/% er Entry [M] L Solvent Yield/% er
1 Ni(NTf2)2 L1 DCE 55 78∶22 14 Ni(NTf2)2 L9 MTBE 40 15∶85
2 Ni(NTf2)2 L1 Toluene 60 82∶18 15 Ni(NTf2)2 L10 MTBE 32 71∶29
3 Ni(NTf2)2 L1 MeCN 21 66∶34 16 Ni(NTf2)2 L11 MTBE 53 73∶27
4 Ni(NTf2)2 L1 DMF Trace 17 Ni(NTf2)2 L12 MTBE 42 85∶15
5 Ni(NTf2)2 L1 THF Trace 18 Ni(NTf2)2 L13 MTBE 51 40∶60
6 Ni(NTf2)2 L1 MTBE 70 90∶10 19 Ni(NTf2)2 L14 MTBE 75 60∶40
7 Ni(NTf2)2 L2 MTBE 46 85∶15 20 Ni(NTf2)2 L15 MTBE 72 49∶51
8 Ni(NTf2)2 L3 MTBE N.R. 21 Ni(NTf2)2 L16 MTBE 65 50∶50
9 Ni(NTf2)2 L4 MTBE 36 88∶12 22 Ni(NTf2)2 L17 MTBE 55 60∶40
10 Ni(NTf2)2 L5 MTBE 29 75∶25 23 Ni(OTf)2 L1 MTBE 72 84∶16
11 Ni(NTf2)2 L6 MTBE 30 88∶12 24 NiBr2 L1 MTBE 45 72∶28
12 Ni(NTf2)2 L7 MTBE 17 75∶25 25 Cu(OTf)2 L1 MTBE 53 53∶47
13 Ni(NTf2)2 L8 MTBE 52 25∶75 26 Zn(OTf)2 L1 MTBE 58 50∶50

a Reaction conditions: 1a (0.05 mmol), 2a (0.075 mmol), Ni catalyst (10 mol%), and ligand (15 mol%) in solvent (1.5 mL) at room temperature for 2d. b Yield of isolated product. c The ee value was determined by HPLC on a chiral stationary phase.

With these acceptable reaction conditions in hand (Table 1, Entry 6), the applicability of the asymmetric higher-order (5+3) annulation of various 2-(2-aminoaryl)indoles was then examined with a wide range of β,γ-unsaturated α-keto- esters (Scheme 2). Initially, 1-(2-indolyl)naphthalen-2- amines bearing a methyl substituent at the C(5) (1b) or C(6) (1c) position of the indole ring were subjected to reaction with 2a, affording corresponding products 3b and 3c in good yields and with enantiomeric ratios of 86∶14 and 88∶12, respectively. Swapping the isopropyl group with a cyclopentyl (Cp) functionality linked by the ester of substrate 2 led to a slight improvement in enantioselectivity, affording product 3d with an enantiomeric ratio of 95∶5. To expand the application of this Ni(II)/Bim catalysis, N-protected 2-(2-aminophenyl)indoles were employed as 1,5-dinucleophilic components to prove their compatibility. Subsequently, the reactions of N-methyl 2-(2-amino- phenyl)indole (1d) and various β,γ-unsaturated α-ketoesters were conducted under standard conditions, among which substituents, such as isopropyl, cyclopentyl (Cp) and cyclohexyl (Cy), tethered by the ester group of substrate 2 were compatible, providing chiral products 3e~3g in good yields and with high enantioselectivity (86∶14 to 90∶10 er). N-Ethyl counterpart 1e was suitable for this transformation, affording product 3h in 70% yield with 86∶14 er. Alternatively, a series of substrates 1 bearing bromo (1f), methoxy (1g), or aryl (1h and 1i) groups at the C(4)-position of the phenyl ring were investigated for their ability to react with β,γ-unsaturated α-ketoesters. All these substrates were well accommodated, confirming the reaction efficiency, as products 3i~3x were obtained in synthetically useful yields and with high enantioselectivity. Among these substrates, cyclopentyl-derived α-ketoesters consistently delivered higher enantioselectivities than isopropyl analogues did (3l vs 3k; 3r vs 3q), indicating the beneficial influence of the bulky cyclopentyl group on asymmetric induction. Moreover, substrate 1, bearing a bulky substituent at the C(4)- position of the phenyl ring, favored the control of the enantioselectivity, as exemplified by its C(4)-aryl counterparts, which resulted in higher er values than those of the C(4)-free substrate (3f vs 3l). Motivated by these distinctive observations, the substrate scope with respect to β,γ-unsatu- rated α-ketoesters was carefully expanded using C(4)-aryl variants. The results indicated that substrates with electronically poor (e.g., chloro and bromo), neutral (H) and rich (e.g., methyl and methoxy) groups at different positions (para and meta) on the phenyl ring were compatible with this catalytic system, furnishing tricyclic indoles 3k~3x with structural diversity in acceptable yields and high enantioselectivities. Notably, excellent diastereoselectivity (dr>19∶1 in all cases) was observed in these saddle-shaped eight-membered aza-heterocycles incorporating both central and axial chirality, and the saddle-shaped configuration was confirmed by X-ray single crystal diffraction analysis of racemic product 3i (Figure 2, CCDC 2531147).
Scheme 2 Substrate scope for the synthesis of products 3 (the dr value was confirmed by 1H NMR analysis)
Figure 2 X-Ray structure of racemic product 3i
To confirm the absolute configuration of these resulting products, the same chiral product 3y reported in the literature was synthesized,[16] and its absolute configuration was unambiguously assigned as R by comparison of its HPLC spectrum (Scheme 3). The results indicate that our developed catalytic system is competent for asymmetric induction with sterically demanding ester substrates, whereas its stereocontrol is significantly diminished with less hindered analogues.
Scheme 3 Determination of the absolute configuration by analogy
To demonstrate the synthetic scalability of this strategy, the reaction between 1h and 2c was scaled up to 0.3 mmol under standard conditions, affording 3l in comparable yield and enantioselectivity (Scheme 4a). Moreover, the cyclization products feature versatile functional handles including imine and ester groups that enable diverse downstream transformations. For example, the reduction of both imine and ester moieties in 3l with NaBH4 in MeOH at room temperature furnished the corresponding alcohol derivative 4 in 80% yield with slightly decreased enantioselectivity and >19∶1 dr (Scheme 4b).
Scheme 4 Scale-up reaction and reduction of 3l
The stereochemical outcome for higher-order (5+3) cyclization can be explained using a model as shown in Scheme 5. The Bim ligand coordinates to Ni in a bidentate fashion through its two nitrogen atoms, forming a six- membered chelate ring. Simultaneously, the two carbonyl oxygen atoms of β,γ-unsaturated α-ketoester coordinates to the same Ni center, giving rise to an additional five-mem- bered chelate ring. The resulting four-coordinate Ni center, ligated by two N and two O atoms, adopts a distorted tetrahedral geometry, which orients the enone moiety of substrate 2 toward phenyl ring I of the Bim ligand. Re-face nucleophilic attack of the indole C(3)-carbon in substrate 1 on the electrophilic β-carbon of the enone moiety in substrate 2 is favorable, yielding intermediate B with central and axial chirality, followed by the dehydration to deliver saddle-shaped eight-membered aza-heterocycle 3a as the dominant conformationally stable product. In contrast, Si-face nucleophilic attack of the indole C(3) carbon on the enone moiety is disfavored due to severe steric repulsion imposed by phenyl ring I.
Scheme 5 Stereochemical model

3 Conclusions

In summary, a Ni(II)/Bim-catalyzed enantioselective higher-order (5+3) cyclization of 2-(2-aminoaryl)indoles with β,γ-unsaturated α-ketoesters was developed, enabling a concerted Friedel-Crafts alkylation/dehydration cascade to access a range of saddle-shaped eight-membered-ring bri- dged aryl-indoles bearing both central and axial chirality. Notably, the protocol is capable of good functional group compatibility and a wide substrate scope and is distinguished by its mild conditions (under ambient conditions) and high stereoselectivities, thus offering a new asymmetric strategy for constructing chiral medium-sized bridged biaryl scaffolds. Ongoing efforts in our laboratory are directed toward expanding the synthetic utility of the Ni/Bim platform to other chiral molecules.

4 Experimental section

4.1 Materials and methods

1H NMR and 13C NMR spectra were measured on a Bruker DPX 400 MHz spectrometer in CDCl3 with chemical shift (δ) given relative to TMS as internal standard. HRMS (APCI and ESI) was determined by using a microTOF-QII HRMS/MS instrument (BRUKER). Starting materials 1[18a] and 2[18b-18d] were synthesized following literature procedures, respectively.

4.2 General procedure for the synthesis of products 3

With the synthesis of 3a, to a 10 mL Schlenk tube under air conditions, Ni(NTf2)2 (10 mol%, 3.1 mg), L1 (15 mol%) and MTBE (1.5 mL) were added, and the mixture was stirred for 1 h at room temperature. Then, 1a (0.05 mmol, 1.0 equiv.) and 2a (0.075 mmol, 1.5 equiv.) were successively added. The mixture was stirred at room temperature about 2 d. After the reaction was completed [indicated by thin-layer chromatography (TLC), petroleum ether/EtOAc, VV=5∶1], the reaction mixture was concentrated by vacuum distillation and purified by flash column chromatography (petroleum ether/acetone, VV=20∶1) to afford the desired pure product 3a as a yellow solid. Compunds 3b~3y were synthesized with the same method.
Isopropyl (R,E)-10-phenyl-10,15-dihydro-9H-naphtho-[2',1':2,3]azocino[4,5-b]indole-8-carboxylate (3a): Yellow solid, 15.6 mg, 70% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$-23.0 (c 0.3, acetone). m.p. 185~186 ℃; 1H NMR (400 MHz, CDCl3) δ: 8.08 (s, 1H), 7.98~7.84 (m, 3H), 7.58~7.49 (m, 2H), 7.47 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.31 (d, J=8.0 Hz, 1H), 7.24~7.17 (m, 3H), 7.14 (t, J=8.0 Hz, 2H), 7.11~7.02 (m, 2H), 5.32~5.15 (m, 1H), 5.07~4.90 (m, 1H), 3.35~3.20 (m, 1H), 2.92 (t, J=12.0 Hz, 1H), 1.42 (d, J=8.0 Hz, 3H), 1.35 (d, J=8.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 163.9, 163.2, 146.6, 144.3, 135.9, 133.5, 129.8, 129.0, 128.7, 128.6, 127.8, 127.5, 127.4, 126.6, 126.5, 125.6, 122.9, 121.6, 119.8, 119.2, 117.7, 117.6, 110.6, 70.3, 40.8, 38.1, 21.9, 21.9; HRMS (ESI) calcd for C31H27N2O2 (M+H)+ 495.2067, found 495.2066. HPLC analysis: 90∶10 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.8 mL/min, λ=254 nm, tR(minor)=7.7 min, tR(major)=24.7 min].
Isopropyl (R,E)-12-methyl-10-phenyl-10,15-dihydro-9H-naphtho[2',1':2,3]azocino[4,5-b]indole-8-carboxylate (3b): Yellow solid, 14.8 mg, 63% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ +161.5 (c 0.5, acetone). m.p. 207~208 ℃; 1H NMR (400 MHz, CDCl3) δ: 8.00~7.85 (m, 4H), 7.56~7.47 (m, 2H), 7.38 (d, J=8.0 Hz, 1H), 7.25~7.18 (m, 4H), 7.15 (t, J=8.0 Hz, 2H), 7.11~7.05 (m, 1H), 7.02 (d, J=8.0 Hz, 1H), 5.28~5.16 (m, 1H), 5.07~4.92 (m, 1H), 3.29~3.20 (m, 1H), 2.89 (t, J=12.0 Hz, 1H), 2.39 (s, 3H), 1.43 (d, J=4.0 Hz, 3H), 1.36 (d, J=4.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 163.7, 163.2, 146.4, 144.4, 134.1, 133.4, 132.0, 129.6, 129.1, 129.0, 128.6, 128.5, 127.9, 127.4, 127.3, 126.5, 125.5, 124.5, 121.5, 118.7, 117.7, 117.1, 110.2, 70.3, 40.6, 38.2, 21.9, 21.8, 21.6; HRMS (ESI) calcd for C32H29N2O2 (M+H)+ 473.2224, found 473.2220. HPLC analysis: 86∶14 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.8 mL/min, λ=254 nm, tR(minor)=4.5 min, tR(major)=4.2 min].
Isopropyl (R,E)-13-methyl-10-phenyl-10,15-dihydro-9H-naphtho[2',1':2,3]azocino[4,5-b]indole-8-carboxylate (3c): Yellow solid, 16.5 mg, 66% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -67.0 (c 0.1, acetone). m.p. 205~207 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.96~7.89 (m, 3H), 7.56~7.48 (m, 2H), 7.39 (d, J=8.0 Hz, 1H), 7.33 (d, J=8.0 Hz, 1H), 7.28~7.26 (m, 1H), 7.23~7.18 (m, 2H), 7.17~7.10 (m, 3H), 7.10~7.03 (m, 1H), 6.89 (d, J=8.0 Hz, 1H), 5.27~5.17 (m, 1H), 5.02~4.93 (m, 1H), 3.32~3.20 (m, 1H), 2.89 (t, J=12.0 Hz, 1H), 2.44 (s, 3H), 1.42 (d, J=6.0 Hz, 3H), 1.36 (d, J=6.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 163.7, 163.2, 146.4, 144.3, 136.2, 133.4, 132.9, 132.0, 129.6, 128.8, 128.6, 128.5, 128.3, 127.4, 127.3, 127.1, 126.5, 125.5, 121.6, 121.4, 118.8, 117.7, 117.5, 110.4, 70.3, 40.7, 38.0, 21.9, 21.8, 21.8; HRMS (ESI) calcd for C32H29N2O2 (M+H)+ 473.2224, found 473.2221. HPLC analysis: 88∶12 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=70∶30, 1 mL/min, λ=254 nm, tR(minor)=5.1 min, tR(major)=4.1 min].
Cyclopentyl (R,E)-10-(4-chlorophenyl)-10,15-dihydro-9H-naphtho[2',1':2,3]azocino[4,5-b]indole-8-carboxylate (3d): Yellow solid, 15.3 mg, 59% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -41.4 (c 0.3, acetone). m.p. 211~212 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.80~7.65 (m, 4H), 7.50 (t, J=8.0 Hz, 2H), 7.42 (t, J=8.0 Hz, 1H), 7.36~7.29 (m, 3H), 7.25~7.22 (m, 1H), 7.19~7.08 (m, 4H), 7.05 (t, J=8.0 Hz, 1H), 5.43~5.31 (m, 1H), 5.01~4.91 (m, 1H), 3.58 (s, 3H), 3.25~3.11 (m, 1H), 2.84 (t, J=12.0 Hz, 1H), 2.09~1.65 (m, 8H); 13C NMR (100 MHz, CDCl3) δ: 163.3, 163.3, 146.5, 142.7, 135.7, 133.3, 132.2, 132.0, 129.9, 129.0, 128.8, 128.7, 128.6, 127.5, 127.5, 126.2, 125.7, 123.1, 121.5, 119.9, 118.8, 117.2, 117.1, 110.6, 40.1, 37.9, 32.8, 32.6, 23.9, 23.9; HRMS (ESI) calcd for C33H28ClN2O2 (M+H)+ 519.1834, found 519.1833. HPLC analysis: 95∶5 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.8 mL/min, λ=254 nm, tR(minor)=4.8 min, tR(major)=4.2 min].
Isopropyl (R,E)-13-methyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3e): Yellow solid, 15.8 mg, 73% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -35.8 (c 1.2, acetone). m.p. 192~193 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.53~7.45 (m, 2H), 7.44~7.35 (m, 2H), 7.31 (d, J=8.0 Hz, 1H), 7.27~7.17 (m, 6H), 7.16~7.09 (m, 1H), 7.05 (t, J=8.0 Hz, 1H), 5.28~5.18 (m, 1H), 5.05~4.95 (m, 1H), 3.52 (s, 3H), 3.30~3.21 (m, 1H), 2.84 (t, J=12.0 Hz, 1H), 1.43 (d, J=8.0 Hz, 3H), 1.39 (d, J=8.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 164.0, 163.2, 149.0, 145.0, 137.8, 133.7, 132.1, 129.0, 128.7, 127.3, 127.1, 126.6, 125.2, 122.5, 122.1, 121.7, 119.6, 119.1, 115.8, 109.4, 70.3, 41.1, 38.6, 31.2, 21.9; HRMS (ESI) calcd for C28H27N2O2 (M+H)+ 423.2067, found 423.2062. HPLC analysis: 87∶13 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=99∶1, 1 mL/ min, λ=254 nm, tR(minor)=32.2 min, tR(major)=44.9 min].
Cyclopentyl (R,E)-13-methyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3f): Yellow solid, 20.3 mg, 71% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ +29.3 (c 0.4, acetone). m.p. 220~222 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.48 (t, J=8.0 Hz, 2H), 7.40~7.33 (m, 2H), 7.29 (t, J=8.0 Hz, 1H), 7.25~7.14 (m, 6H), 7.14~7.08 (m, 1H), 7.03 (t, J=8.0 Hz, 1H), 5.42~5.31 (m, 1H), 5.00~4.91 (m, 1H), 3.51 (s, 3H), 3.23~3.13 (m, 1H), 2.82 (t, J=12.0 Hz, 1H), 2.03~1.92 (m, 2H), 1.91~1.59 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.0, 163.4, 149.0, 144.9, 137.8, 133.6, 132.1, 129.0, 128.7, 127.3, 127.0, 126.6, 125.1, 122.5, 122.0, 121.7, 119.6, 119.0, 115.7, 109.4, 79.4, 41.1, 38.7, 32.9, 32.6, 31.2, 24.0, 23.9; HRMS (ESI) calcd for C30H29N2O2 (M+H)+ 449.2224, found 449.2220. HPLC analysis: 90∶10 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.7 mL/min, λ=254 nm, tR(minor)=8.9 min, tR(major)=9.6 min].
Cyclohexyl (R,E)-13-methyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3g): Yellow solid, 20.9 mg, 71% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -38.1 (c 0.2, acetone). m.p. 220~222 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.49 (d, J=8.0 Hz, 2H), 7.41~7.34 (m, 2H), 7.30 (d, J=8.0 Hz, 1H), 7.27~7.16 (m, 6H), 7.16~7.09 (m, 1H), 7.04 (t, J=8.0 Hz, 1H), 5.07~4.93 (m, 2H), 3.51 (s, 3H), 3.29~3.16 (m, 1H), 2.85 (t, J=12.0 Hz, 1H), 2.04~1.93 (m, 2H), 1.89~1.76 (m, 2H), 1.73~1.32 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.0, 162.9, 148.9, 144.9, 137.7, 133.6, 132.0, 129.0, 128.6, 127.3, 127.0, 126.5, 125.1, 122.4, 122.0, 121.6, 119.5, 119.0, 115.7, 109.4, 75.1, 41.1, 38.7, 31.5, 31.5, 31.1, 25.4, 23.9; HRMS (ESI) calcd for C31H31N2O2 (M+H)+ 463.2380, found 463.2378. HPLC analysis: 86∶14 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.7 mL/min, λ=254 nm, tR(minor)=9.0 min, tR(major)=10.9 min].
Cyclopentyl (R,E)-13-ethyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3h): Yellow solid, 16.1 mg, 70% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -116.8 (c 0.9, acetone). m.p. 149~150 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.54 (d, J=8.0 Hz, 1H), 7.48 (t, J=8.0 Hz, 1H), 7.43~7.31 (m, 3H), 7.25~7.15 (m, 6H), 7.15~7.09 (m, 1H), 7.04 (t, J=8.0 Hz, 1H), 5.41~5.31 (m, 1H), 5.02~4.90 (m, 1H), 4.07~3.94 (m, 2H), 3.23~3.11 (m, 1H), 2.82 (t, J=12.0 Hz, 1H), 2.03~1.93 (m, 2H), 1.93~1.66 (m, 6H), 1.16 (t, J=4.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.2, 149.0, 144.8, 136.8, 133.2, 131.6, 129.0, 128.6, 127.4, 127.3, 126.5, 125.1, 122.3, 121.9, 119.5, 119.0, 116.0, 109.8, 79.3, 41.1, 38.8, 38.7, 32.9, 32.6, 23.9, 23.9, 15.2; HRMS (ESI) calcd for C31H31N2O2 (M+H)+ 463.2380, found 463.2377. HPLC analysis: 86∶14 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50∶50, 0.8 mL/min, λ=254 nm, tR(minor)=5.8 min, tR(major)=5.2 min].
Cyclopentyl (R,E)-2-bromo-13-methyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3i): Yellow solid, 18.9 mg, 72% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -116.0 (c 1.7, acetone). m.p. 195~196 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.66 (s, 1H), 7.59 (d, J=8.0 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 7.33~7.28 (m, 1H), 7.27~7.20 (m, 3H), 7.17~7.11 (m, 3H), 7.05 (t, J=8.0 Hz, 1H), 5.44~5.30 (m, 1H), 5.03~4.93 (m, 1H), 3.54 (s, 3H), 3.27~3.17 (m, 1H), 2.81 (t, J=12.0 Hz, 1H), 2.07~1.65 (m, 8H); 13C NMR (100 MHz, CDCl3) δ: 164.4, 163.1, 147.9, 144.5, 137.9, 134.4, 132.1, 132.0, 128.7, 127.2, 126.9, 126.7, 123.8, 123.7, 122.9, 119.8, 119.2, 118.2, 116.4, 109.5, 79.5, 41.0, 38.6, 32.9, 32.6, 31.3, 23.9, 23.9; HRMS (ESI) calcd for C30H28BrN2O2 (M+H)+ 527.1329, found 527.1328. HPLC analysis: 91∶9 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.9 mL/min, λ=254 nm, tR(minor)=6.1 min, tR(major)=8.0 min].
Cyclopentyl (R,E)-2-methoxy-13-methyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3j): Yellow solid, 14.5 mg, 61% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ +40.4 (c 1.3, acetone). m.p. 170~171 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.36 (d, J=8.0 Hz, 1H), 7.30~7.26 (m, 1H), 7.24~7.15 (m, 6H), 7.14~7.08 (m, 1H), 7.07~6.98 (m, 3H), 5.35 (s, 1H), 4.98~4.89 (m, 1H), 3.90 (s, 3H), 3.51 (s, 3H), 3.19~3.11 (m, 1H), 2.85 (t, J=12.0 Hz, 1H), 2.04~1.92 (m, 2H), 1.90~1.62 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 163.8, 163.5, 157.0, 144.9, 142.5, 137.9, 133.6, 128.7, 127.3, 127.0, 126.6, 123.6, 122.8, 122.6, 119.6, 119.1, 117.1, 115.9, 114.7, 109.4, 79.3, 55.7, 41.0, 38.6, 32.9, 32.6, 31.3, 24.0, 23.9; HRMS (ESI) calcd for C31H31N2O3 (M+H)+ 479.2329, found 479.2328. HPLC analysis: 84∶16 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.7 mL/min, λ=254 nm, tR(minor)=7.5 min, tR(major)=8.7 min].
Isopropyl (R,E)-13-methyl-3,8-diphenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3k): Yellow solid, 17.4 mg, 70% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -210.5 (c 0.6, acetone). m.p. 197~198 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.80~7.70 (m, 4H), 7.54 (t, J=8.0 Hz, 2H), 7.44 (d, J=8.0 Hz, 2H), 7.38~7.32 (m, 2H), 7.29~7.21 (m, 5H), 7.19~7.11 (m, 1H), 7.08 (t, J=8.0 Hz, 1H), 5.36~5.21 (m, 1H), 5.13~4.98 (m, 1H), 3.61 (s, 3H), 3.38~3.24 (m, 1H), 2.94 (t, J=12.0 Hz, 1H), 1.46 (d, J=4.0 Hz, 3H), 1.42 (d, J=4.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.2, 148.1, 144.9, 140.0, 138.0, 137.9, 133.6, 130.4, 129.1, 128.7, 127.8, 127.7, 127.3, 127.0, 126.6, 122.7, 122.6, 122.2, 119.6, 119.2, 116.0, 109.5, 70.4, 41.1, 38.6, 31.3, 21.9, 21.9; HRMS (ESI) calcd for C34H31N2O2 (M+H)+: 499.2380, found 499.2378. HPLC analysis: 87∶13 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50/50, 0.8 mL/min, λ=254 nm, tR(minor)=6.9 min, tR(major)=5.6 min].
Cyclopentyl (R,E)-13-methyl-3,8-diphenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3l): Yellow solid, 16.5 mg, 63% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -201.1 (c 1.1, acetone). m.p. 207~208 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.77~7.68 (m, 4H), 7.52 (t, J=8.0 Hz, 2H), 7.45~7.38 (m, 2H), 7.36~7.29 (m, 2H), 7.26~7.17 (m, 5H), 7.16~7.09 (m, 1H), 7.05 (t, J=8.0 Hz, 1H), 5.39 (s, 1H), 5.04~4.96 (m, 1H), 3.59 (s, 3H), 3.27~3.18 (m, 1H), 2.92 (t, J=12.0 Hz, 1H), 2.08~1.96 (m, 2H), 1.95~1.67 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.3, 148.2, 144.9, 140.1, 138.0, 137.9, 133.6, 130.4, 129.1, 128.7, 127.8, 127.3, 127.1, 126.6, 122.7, 122.6, 122.2, 119.7, 119.1, 115.9, 109.5, 79.4, 41.1, 38.8, 32.9, 32.6, 31.3, 24.0, 23.9; HRMS (ESI) calcd for C36H33N2O2 (M+H)+ 525.2537, found 525.2535. HPLC analysis: 93∶7 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60/40, 0.8 mL/min, λ=254 nm, tR(minor)=6.6 min, tR(major)=7.6 min]/
Cyclohexyl (R,E)-13-methyl-3,8-diphenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3m): Yellow solid, 17.6 mg, 68% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -226.1 (c 0.6, acetone). m.p. 235~236 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.77~7.66 (m, 4H), 7.51 (t, J=8.0 Hz, 2H), 7.44~7.36 (m, 2H), 7.32 (t, J=8.0 Hz, 2H), 7.26~7.16 (m, 5H), 7.15~7.08 (m, 1H), 7.04 (t, J=8.0 Hz, 1H), 5.07~4.94 (m, 2H), 3.58 (s, 3H), 3.30~3.21 (m, 1H), 2.92 (t, J=12.0 Hz, 1H), 1.98 (s, 2H), 1.82 (s, 2H), 1.70~1.34 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.0, 162.9, 148.9, 144.9, 137.7, 133.6, 132.0, 129.0, 128.6, 127.3, 127.0, 126.5, 125.1, 122.4, 122.0, 121.6, 119.5, 119.0, 115.7, 109.4, 75.1, 41.1, 38.7, 31.5, 31.5, 31.1, 25.4, 23.9; HRMS (ESI) calcd for C37H35N2O2 (M+H)+ 539.2693, found 539.2690. HPLC analysis: 95∶5 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=70/30, 0.8 mL/min, λ=254 nm, tR(minor)=9.8 min, tR(major)=4.8 min].
Cyclopentyl (R,E)-8-(4-chlorophenyl)-13-methyl-3-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3n): Yellow solid, 20.4 mg, 72% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -248.4 (c 0.6, acetone). m.p. 143~145 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.80~7.65 (m, 4H), 7.50 (t, J=8.0 Hz, 2H), 7.42 (t, J=8.0 Hz, 1H), 7.36~7.29 (m, 3H), 7.25~7.22 (m, 1H), 7.19~7.08 (m, 4H), 7.05 (t, J=8.0 Hz, 1H), 5.43~5.31 (m, 1H), 5.01~4.91 (m, 1H), 3.58 (s, 3H), 3.25~3.11 (m, 1H), 2.84 (t, J=12.0 Hz, 1H), 2.09~1.65 (m, 8H); 13C NMR (100 MHz, CDCl3) δ: 163.6, 163.3, 148.0, 143.3, 139.9, 138.1, 137.8, 133.6, 132.2, 130.3, 129.1, 128.8, 128.6, 127.8, 127.0, 126.8, 126.4, 122.7, 121.9, 119.7, 118.8, 115.4, 109.5, 79.5, 40.5, 38.5, 32.8, 32.5, 31.3, 23.9, 23.9; HRMS (ESI) calcd for C36H32ClN2O2 (M+H)+ 559.2147, found 559.2143. HPLC analysis: 93∶7 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50∶50, 0.8 mL/min, λ=254 nm, tR(minor)=8.8 min, tR(major)=6.0 min].
Cyclopentyl (R,E)-8-(3-chlorophenyl)-13-methyl-3-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3o): Yellow solid, 19.4 mg, 70% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -210.9 (c 0.9, acetone). m.p. 197~198 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.78~7.68 (m, 4H), 7.51 (t, J=8.0 Hz, 2H), 7.44~7.36 (m, 2H), 7.33 (d, J=8.0 Hz, 2H), 7.27 (t, J=8.0 Hz, 1H), 7.20 (s, 1H), 7.17~7.04 (m, 4H), 5.45~5.34 (m, 1H), 5.05~4.92 (m, 1H), 3.58 (s, 3H), 3.28~3.15 (m, 1H), 2.88 (t, J=12.0 Hz, 1H), 2.04~1.65 (m, 8H); 13C NMR (100 MHz, CDCl3) δ: 163.6, 163.3, 148.0, 147.0, 139.9, 138.3, 137.8, 134.4, 133.7, 130.4, 130.0, 129.1, 127.9, 127.8, 127.5, 127.1, 126.8, 126.8, 125.5, 122.7, 122.7, 121.9, 119.8, 118.8, 115.2, 109.6, 79.5, 40.8, 38.6, 32.9, 32.6, 31.3, 24.0, 23.9; HRMS (ESI) calcd for C36H32- ClN2O2 (M+H)+ 559.2147, found 559.2145. HPLC analysis: 95∶5 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50∶50, 0.8 mL/min, λ=254 nm, tR(minor)=8.7 min, tR(major)=6.3 min].
Cyclopentyl (R,E)-8-(4-methoxyphenyl)-13-methyl-3-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3p): Yellow solid, 11.6 mg, 42% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -72.4 (c 0.4, acetone). m.p. 113~115 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.74~7.66 (m, 4H), 7.50 (t, J=8.0 Hz, 2H), 7.44~7.35 (m, 2H), 7.30 (d, J=8.0 Hz, 2H), 7.22 (t, J=8.0 Hz, 1H), 7.09 (d, J=8.0 Hz, 2H), 7.04 (t, J=8.0 Hz, 1H), 6.73 (d, J=8.0 Hz, 2H), 5.37 (s, 1H), 4.99~4.90 (m, 1H), 3.69 (s, 3H), 3.57 (s, 3H), 3.23~3.15 (m, 1H), 2.86 (t, J=12.0 Hz, 1H), 2.03~1.93 (m, 2H), 1.90~1.66 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.4, 158.2, 148.1, 140.1, 138.0, 137.1, 130.4, 129.1, 128.2, 127.7, 127.0, 122.7, 122.6, 122.2, 119.6, 119.1, 116.3, 114.1, 109.5, 79.4, 55.3, 40.3, 38.9, 32.9, 32.6, 31.3, 24.0, 23.9; HRMS (ESI) calcd for C37H35N2O3 (M+H)+ 555.2642, found 555.2640. HPLC analysis: 86∶14 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.7 mL/min, λ=254 nm, tR(minor)=7.3 min, tR(major)=8.5 min].
Isopropyl (R,E)-13-methyl-8-phenyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3q): Yellow solid, 18.9 mg, 73% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -88.3 (c 0.7, acetone). m.p. 246~247 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.75~7.70 (m, 2H), 7.60 (d, J=8.0 Hz, 2H), 7.40 (d, J=8.0 Hz, 1H), 7.32 (d, J=8.0 Hz, 4H), 7.26~7.18 (m, 5H), 7.12 (s, 1H), 7.05 (t, J=8.0 Hz, 1H), 5.32~5.19 (m, 1H), 5.07~4.94 (m, 1H), 3.59 (s, 3H), 3.32~3.23 (m, 1H), 2.92 (t, J=12.0 Hz, 1H), 2.45 (s, 3H), 1.44 (d, J=8.0 Hz, 3H), 1.40 (d, J=8.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.2, 147.9, 144.9, 138.0, 137.9, 137.6, 133.7, 130.2, 129.9, 128.7, 127.5, 127.4, 127.1, 126.9, 126.6, 122.7, 122.6, 122.2, 119.6, 119.2, 115.9, 109.5, 70.3, 41.1, 38.7, 31.3, 21.9, 21.3; HRMS (ESI) calcd for C35H33N2O2 (M+H)+ 513.2537, found 513.2535. HPLC analysis: 95∶5 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50∶50, 0.8 mL/ min, λ=254 nm, tR(minor)=6.5 min, tR(major)=5.2 min].
Cyclopentyl (R,E)-13-methyl-8-phenyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3r): Yellow solid, 17.9 mg, 69% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ +130.0 (c 0.9, acetone). m.p. 264~265 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.75~7.67 (m, 2H), 7.58 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 1H), 7.34~7.27 (m, 4H), 7.25~7.16 (m, 5H), 7.13~7.08 (m, 1H), 7.03 (t, J=8.0 Hz, 1H), 5.37 (s, 1H), 5.03~4.93 (m, 1H), 3.57 (s, 3H), 3.24~3.15 (m, 1H), 2.90 (t, J=12.0 Hz, 1H), 2.43 (s, 3H), 2.04~1.93 (m, 2H), 1.92~1.63 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.4, 158.2, 148.1, 140.1, 138.0, 137.1, 130.4, 129.1, 128.2, 127.7, 127.0, 122.7, 122.6, 122.2, 119.6, 119.1, 116.3, 114.1, 109.5, 79.4, 55.3, 40.3, 38.9, 32.9, 32.6, 31.3, 24.0, 23.9; HRMS (ESI) calcd for C37H35N2O2 (M+H)+ 539.2693, found 539.2691. HPLC analysis: 97∶3 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.7 mL/min, λ=254 nm, tR(minor)=9.1 min, tR(major)=11.6 min].
Cyclohexyl (R,E)-13-methyl-8-phenyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3s): Yellow solid, 18.5 mg, 67% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -164.2 (c 0.7, acetone). m.p. 176~177 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.76~7.69 (m, 2H), 7.60 (d, J=8.0 Hz, 2H), 7.39 (d, J=8.0 Hz, 1H), 7.32 (d, J=8.0 Hz, 4H), 7.26~7.17 (m, 5H), 7.15~7.08 (m, 1H), 7.05 (t, J=8.0 Hz, 1H), 5.09~4.95 (m, 2H), 3.58 (s, 3H), 3.31~3.20 (m, 1H), 2.93 (t, J=12.0 Hz, 1H), 2.45 (s, 3H), 2.04~1.91 (m, 2H), 1.89~1.78 (m, 2H), 1.71~1.35 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 162.9, 147.9, 145.0, 138.0, 137.9, 137.6, 137.2, 133.7, 130.2, 129.8, 128.7, 127.5, 127.3, 127.1, 126.9, 126.6, 122.7, 122.6, 122.2, 119.6, 119.1, 115.9, 109.5, 75.1, 41.1, 38.8, 31.6, 31.6, 31.3, 25.4, 23.9, 21.3; HRMS (ESI) calcd for C38H37N2O2 (M+H)+ 553.2850, found 553.2857. HPLC analysis: 98∶2 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.7 mL/min, λ=254 nm, tR(minor)=11.9 min, tR(major)=17.0 min].
Cyclopentyl (R,E)-13-methyl-3,8-di-p-tolyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3t): Yellow solid, 14.9 mg, 54% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -88.9 (c 1.1, acetone). m.p. 251~252 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.70 (d, J=7.2 Hz, 2H), 7.59 (d, J=8.0 Hz, 2H), 7.39 (d, J=8.0 Hz, 1H), 7.34~7.28 (m, 4H), 7.24 (t, J=8.0 Hz, 1H), 7.10~6.99 (m, 5H), 5.38 (s, 1H), 5.01~4.93 (m, 1H), 3.57 (s, 3H), 3.24~3.16 (m, 1H), 2.89 (t, J=12.0 Hz, 1H), 2.44 (s, 3H), 2.23 (s, 3H), 2.05~1.95 (m, 2H), 1.93~1.68 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.4, 147.9, 141.9, 138.0, 137.9, 137.6, 137.2, 136.1, 133.6, 130.2, 129.8, 129.4, 127.5, 127.2, 127.1, 126.9, 122.6, 122.5, 122.2, 119.6, 119.1, 116.1, 109.5, 79.4, 40.7, 38.8, 32.9, 32.6, 31.3, 24.0, 23.9, 21.3, 21.1; HRMS (ESI) calcd for C38H37N2O2 (M+H)+ 553.2850, found 553.2848. HPLC analysis: 85∶15 er [Daicel Chiralpak IA, hexane/ i-PrOH, VV=60∶40, 1 mL/min, λ=254 nm, tR(minor)=6.3 min, tR(major)=7.9 min].
Cyclopentyl (R,E)-8-(4-methoxyphenyl)-13-methyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3u): Yellow solid, 11.6 mg, 47% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -116.5 (c 0.9, acetone). m.p. 155~156 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.74~7.69 (m, 2H), 7.60 (d, J=8.0 Hz, 2H), 7.39 (d, J=8.0 Hz, 1H), 7.32 (d, J=8.0 Hz, 4H), 7.24 (t, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 2H), 7.05 (t, J=8.0 Hz, 1H), 6.74 (d, J=8.0 Hz, 2H), 5.43~5.35 (m, 1H), 5.01~4.90 (m, 1H), 3.71 (s, 3H), 3.58 (s, 3H), 3.20 (t, J=12.0, 8.0 Hz, 1H), 2.88 (t, J=12.0 Hz, 1H), 2.44 (s, 3H), 2.05~1.95 (m, 2H), 1.94~1.66 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 164.1, 163.4, 158.2, 147.9, 137.9, 137.9, 137.6, 137.2, 137.1, 133.5, 130.2, 129.8, 128.2, 127.5, 127.1, 126.9, 122.7, 122.6, 122.2, 119.6, 119.1, 116.2, 114.1, 109.5, 79.4, 55.3, 40.3, 38.9, 32.9, 32.6, 31.3, 24.0, 23.9, 21.3, 14.2; HRMS (ESI) calcd for C38H37N2O3 (M+H)+ 569.2799, found 569.2798. HPLC analysis: 88∶12 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.8 mL/min, λ=254 nm, tR(minor)=10.0 min, tR(major)=12.1 min].
Cyclopentyl (R,E)-8-(4-chlorophenyl)-13-methyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6- carboxylate (3v): Yellow solid, 16.6 mg, 59% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -119.2 (c 0.8, acetone). m.p. 176~177 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.73~7.68 (m, 2H), 7.58 (d, J=8.0 Hz, 2H), 7.36~7.29 (m, 5H), 7.26~7.22 (m, 1H), 7.19~7.10 (m, 4H), 7.05 (t, J=8.0 Hz, 1H), 5.41~5.33 (m, 1H), 5.00~4.92 (m, 1H), 3.57 (s, 3H), 3.22~3.15 (m, 1H), 2.85 (t, J=12.0 Hz, 1H), 2.44 (s, 3H), 2.04~1.94 (m, 2H), 1.90~1.66 (m, 6H).;13C NMR (100 MHz, CDCl3) δ: 163.6, 163.4, 147.8, 143.4, 138.1, 137.9, 137.7, 137.1, 133.7, 132.3, 130.1, 129.9, 128.9, 128.7, 127.6, 126.9, 122.7, 121.9, 119.8, 118.9, 115.4, 109.6, 79.5, 40.5, 38.6, 32.9, 32.6, 31.3, 24.0, 23.9, 21.3; HRMS (ESI) calcd for C37H34ClN2O2 (M+H)+ 573.2303, found 573.2300. HPLC analysis: 95∶5 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50/50, 0.8 mL/min, λ=254 nm, tR(minor)=8.0 min, tR(major)=5.9 min].
Cyclopentyl (R,E)-8-(3-chlorophenyl)-13-methyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6- carboxylate (3w): Yellow solid, 19.8 mg, 68% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -276.6 (c 1.0, acetone). m.p. 259~260 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.73~7.69 (m, 2H), 7.59 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 1H), 7.34~7.28 (m, 4H), 7.26~7.21 (m, 1H), 7.18 (s, 1H), 7.14~7.04 (m, 4H), 5.40~5.32 (m, 1H), 5.00~4.91 (m, 1H), 3.56 (s, 3H), 3.26~3.14 (m, 1H), 2.86 (t, J=12.0 Hz, 1H), 2.43 (s, 3H), 2.05~1.95 (m, 2H), 1.90~1.66 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 163.6, 163.3, 147.8, 147.0, 138.3, 137.7, 137.1, 134.4, 133.8, 130.2, 130.0, 129.8, 127.7, 127.6, 126.9, 126.8, 125.5, 122.7, 122.7, 121.9, 119.8, 118.8, 115.2, 109.6, 79.5, 40.9, 38.6, 32.9, 32.6, 31.3, 24.0, 23.9, 21.3; HRMS (ESI) calcd for C37H34ClN2O2 (M+H)+ 573.2303, found 573.2301. HPLC analysis: 91∶9 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 0.8 mL/min, λ=254 nm, tR(minor)=6.5 min, tR(major)=8.2 min].
Cyclopentyl (R,E)-8-(4-bromophenyl)-13-methyl-3-(p-tolyl)-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3x): Yellow solid, 18.8 mg, 61% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -105.5 (c 0.2, acetone). m.p. 157~158 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.74~7.68 (m, 2H), 7.57 (d, J=8.0 Hz, 2H), 7.36~7.28 (m, 7H), 7.26~7.21 (m, 1H), 7.06 (d, J=8.0 Hz, 3H), 5.40~5.33 (m, 1H), 4.99~4.91 (m, 1H), 3.57 (s, 3H), 3.52~3.47 (m, 1H), 3.23~3.14 (m, 1H), 2.85 (t, J=12.0 Hz, 1H), 2.44 (s, 3H), 2.05~1.94 (m, 2H), 1.92~1.64 (m, 6H); 13C NMR (100 MHz, CDCl3) δ: 163.6, 163.4, 147.8, 143.9, 138.1, 137.9, 137.7, 137.0, 133.7, 131.8, 130.1, 129.9, 129.1, 127.7, 126.9, 122.7, 121.9, 120.3, 119.8, 118.9, 115.3, 109.6, 79.5, 66.0, 40.6, 38.5, 32.9, 32.6, 31.3, 24.0, 23.9, 21.3, 15.4; HRMS (ESI) calcd for C37H34BrN2O2 (M+H)+ 617.1798, found 617.1796. HPLC analysis: 90∶10 er [Daicel Chiralpak IA, hexane/i-PrOH, VV=60∶40, 1 mL/min, λ=254 nm, tR(minor)=8.3 min, tR(major)=10.7 min].
Methyl (R,E)-13-methyl-8-phenyl-8,13-dihydro-7H-benzo[2,3]azocino[4,5-b]indole-6-carboxylate (3y): Yellow solid, 14.4 mg, 73% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -88.2 (c 2.2, CHCl3). m.p. 137~138 ℃; 1H NMR (400 MHz, CDCl3) δ: 7.49 (t, J=8.0 Hz, 2H), 7.39 (d, J=8.0 Hz, 2H), 7.29 (d, J=8.0 Hz, 1H), 7.25~7.17 (m, 6H), 7.14~7.08 (m, 1H), 7.04 (t, J=8.0 Hz, 1H), 5.01~4.90 (m, 1H), 3.89 (s, 3H), 3.50 (s, 3H), 3.33~3.25 (m, 1H), 2.81 (t, J=12.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ: 164.2, 163.5, 148.6, 144.8, 137.8, 133.5, 132.1, 129.1, 128.7, 127.3, 127.0, 126.6, 125.4, 122.6, 121.9, 121.7, 119.6, 119.2, 115.9, 109.4, 53.3, 40.8, 38.3, 31.1, 27.0; HRMS (ESI) calcd for C26H23N2O2 (M+H)+ 395.1754, found 395.1752. HPLC analysis: 80∶20 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=70∶30, 1 mL/min, λ=254 nm, tR(minor)=7.0 min, tR(major)=6.5 min].

4.3 Scale-up transformation of product 3l

To a 10 mL Schlenk tube under air conditions, Ni(NTf2)2 (10 mol %, 18.6 mg), L1 (15 mol%) and MTBE (1.5 mL) were added, and the mixture was stirred for 1 h at room temperature. Then, 1h (0.3 mmol, 1.0 equiv) and 2c (0.45 mmol, 1.5 equiv) were successively added. The mixture was stirred at room temperature about 3 d. After the reaction was completed (indicated by TLC, PE/EtOAc, VV=5∶1), the reaction mixture was concentrated by vacuum distillation and purified by flash column chromatography (petroleum ether/acetone, VV=20∶1) to afford the desired pure product 3l.

4.4 Transformation of product 4

To a solution of 3l (52.4 mg, 0.1 mmol) in MeOH (1.0 mL) and DCM (1.0 mL) was added NaBH4 (5.0 equiv.). The mixture was stirred at room temperature for 1 h. After completion, the reaction was quenched with saturated NH4Cl solution and extracted with DCM (5 mL×3). The combined organic layers were dried with Na2SO4, and the solvent was evaporated under a vacuum. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc, VV=5∶1) to afford pure product ((8R)-13-methyl-2,8-diphenyl-6,7,8,13-tetrahydro- 5H-benzo[2,3]azocino[4,5-b]indol-6-yl)methanol (4), Wh- ite solid, 35.6 mg, 80% yield. ${[\alpha ]}_{\text{D}}^{\text{20}}$ -40.1 (c 0.7, acetone). m.p. 260~261 ℃; 1H NMR (400 MHz, DMSO-d6) δ: 7.7 (d, J=8.0 Hz, 2H), 7.5~7.5 (m, 2H), 7.4~7.3 (m, 7H), 7.3~7.2 (m, 2H), 7.0 (t, J=8.0 Hz, 1H), 7.0 (d, J=8.0 Hz, 1H), 6.7 (t, J=8.0 Hz, 1H), 6.4 (d, J=8.0 Hz, 1H), 5.8 (d, J=7.2 Hz, 1H), 4.7 (t, J=8.0 Hz, 1H), 4.6~4.4 (m, 1H), 3.8 (s, 3H), 3.5~3.4 (m, 2H), 3.2~3.0 (m, 1H), 2.0~1.8 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ: 148.8, 143.8, 140.3, 138.4, 131.6, 129.3, 128.6, 128.0, 127.5, 126.8, 126.5, 126.4, 125.9, 125.3, 121.0, 119.3, 119.0, 118.7, 113.2, 111.3, 110.4, 65.0, 60.2, 54.1, 38.3, 32.7, 32.1; HRMS (ESI) calcd for C31H29N2O (M+H)+ 445.2274, found 445.2271. HPLC analysis: 91∶9 er [Daicel Chiralpak OD-H, hexane/i-PrOH, VV=50∶50, 0.7 mL/min, λ=254 nm, tR(minor)=8.4 min, tR(major)=6.8 min].
Supporting Information 1H NMR, 13C NMR spectra and chiral HPLC spectra of products 3a~3y and 4. The Supporting Information is available free of charge via the Internet at http://sioc-journal.cn.
(Zhao, C.)
[1]
(a) Bringmann, G.; Gulder, T.; Gulder, T. A. M.; Breuning, M. Chem. Rev. 2011, 111, 563.

DOI

(b) Tajuddeen, N.; Feineis, D.; Ihmels, H.; Bringmann, G. Acc. Chem. Res. 2022, 55, 2370.

DOI

(c) Baudoin, O.; Gueritte, F. Stud. Nat. Prod. Chem. 2003, 29, 355.

(d) Tajuddeen, N.; Bringmann, G. Nat. Prod. Rep. 2021, 38, 2154.

DOI PMID

[2]
(a) Basilaia, M.; Chen, M. H.; Secka, J.; Gustafson, J. L. Acc. Chem. Res. 2022, 55, 2904.

DOI

(b) Bremner, J. B.; Keller, P. A.; Pyne, S. G.; Boyle, T. P.; Brkic, Z.; Morgan, J.; Somphol, K.; Coates, J. A.; Deadman, J.; Rhodes, D. I. Bioorg. Med. Chem. 2010, 18, 2611.

DOI

[3]
(a) Kumar, A.; Sasai, H.; Takizawa, S. Acc. Chem. Res. 2022, 55, 2949

DOI

(b) Parmar, D.; Sugiono, E.; Raja, S.; Rueping, M. Chem. Rev. 2014, 114, 9047.

DOI PMID

(c) Cheng, K. J.; Tan, B. Chem. Rec. 2023, 23, e202300147.

DOI

(d) Chen, W.; Zhong, X.; Xing, J.; Wu, C.; Gao, Y. Chin. J. Org. Chem. 2024, 44, 349 (in Chinese).

(陈宛婷, 钟雄威, 邢佳乐, 吴昌书, 高杨, 有机化学, 2024, 44, 349.)

DOI

[4]
(a) Zhang, H. H.; Shi, F. Acc. Chem. Res. 2022, 55, 2562.

DOI

(b) Mei, G. J.; Koay, W. L.; Guan, C. Y.; Lu, Y. Chem 2022, 8, 1855.

DOI

(c) Cheng, J. K.; Xiang, S. H.; Li, S.; Ye, L.; Tan, B. Chem. Rev. 2021, 121, 4805.

DOI

(d) Carmona, J. A.; Rodriguez-Franco, C.; Fernandez, R.; Hornillos, V.; Lassaletta, J. M. Chem. Soc. Rev. 2021, 50, 2968.

DOI PMID

(e) Liao, G.; Shi, B. F. Acc. Chem. Res. 2025, 58, 1562.

DOI

(f) Wang, J.; Wang, Z.; He, W.; Ye, L. Chin. J. Org. Chem. 2024, 44, 1786 (in Chinese).

DOI

(王家晟, 王泽树, 何卫民, 叶龙武, 有机化学, 2024, 44, 1786.)

DOI

(h) Jiang. Q. Chin. J. Org. Chem. 2024, 44, 159 (in Chinese).

(姜权彬, 有机化学, 2024, 44, 159.)

DOI

[5]
(a) Kotwal, N.; Chauhan, P. Chem. Commun. 2022, 58, 11031.

DOI

(b) Tabata, H.; Suzuki, H.; Akiba, K. J. Org. Chem. 2010, 75, 5984.

DOI

[6]
Bringmann, G.; Mortimer, A. J. P.; Keller, P. A.; Gresser, M. J.; Garner, J.; Breuning, M. Angew. Chem., Int. Ed. 2005, 44, 5384.

DOI

[7]
De Ceuninck van Capelle, L. A.; Macdonald, J. M.; Hyland, C. J. T. Org. Biomol. Chem. 2021, 19, 7098.

DOI PMID

[8]
(a) Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Med. Res. Rev. 2008, 28, 155.

PMID

(b) Liao, G.; Yao, Q. J.; Zhang, Z. Z.; Wu, Y. J.; Huang, D. Y.; Shi, B. F. Angew. Chem., Int. Ed. 2018, 57, 3661.

DOI

(c) Shemet, A.; Carreira, E. M. Org. Lett. 2017, 19, 5529.

DOI

(d) Altemoeller, M.; Gehring, T.; Cudaj, J.; Podlech, J.; Goesmann, H.; Feldmann, C.; Rothenberger, A. Eur. J. Org. Chem. 2009, 2009, 2130.

DOI

(e) Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H. J. J.; Zhang, L.; Higgins, G. A.; Parker, E. M. J. Biol. Chem. 2004, 279, 12876.

DOI

[9]
Zhang, Y.; Liu, Y. Q.; Hu, L.; Zhang, X.; Yin, Q. Org. Lett. 2020, 22, 6479.

DOI PMID

[10]
Lu, S. C.; Ong, J. Y.; Yang, H.; Poh, S. B.; Liew, X.; Seow, C. S. D.; Wong, M. W.; Zhao, Y. J. Am. Chem. Soc. 2019, 141, 17062.

DOI

[11]
Cheng, Y.; Li, J.; Ni, Q. Org. Lett. 2025, 27, 13579

DOI

[12]
(a) Illuminati, G.; Mandolini, L. Acc. Chem. Res. 1981, 14, 95.

DOI

(b) Molander, G. A. Acc. Chem. Res. 1998, 31, 603.

DOI

(c) Yet, L. Chem. Rev. 2000, 100, 2963.

PMID

(d) Cui, C. C.; Shi, S. Q.; Wang, L. Y.; Lin, F.; Tu, M. S.; Hao, W. J.; Jiang, B. Chin. Chem. Lett. 2025, 36, 110541.

DOI

(e) Pan, X.; Huang, Y. Chin. J. Org. Chem. 2024, 44, 3609 (in Chinese).

DOI

(潘旭玲, 黄有, 有机化学, 2024, 44, 3609.)

DOI

[13]
(a) Shi, S.-Q.; Cui, C.-C.; Xu, L.-L.; Zhang, J.-P.; Hao, W.-J.; Wang, J.; Jiang, B. Nat. Commun. 2024, 15, 8474.

DOI

(b) Guan, C.-Y.; Zou, S.; Luo, C.; Li, Z.-Y.; Huang, M.; Huang, L.; Xiao, X.; Wei, D.; Wang, M.-C.; Mei, G.-J. Nat. Commun. 2024, 15, 4580.

DOI

[14]
(a) Wang, J. Y.; Li, M. W.; Li, M. F.; Hao, W. J.; Li, G.; Tu, S. J.; Jiang, B. Org. Lett. 2018, 20, 6616.

DOI PMID

(b) Miao, A. Q.; Zhou, M.; Chen, J. L.; Wang, S. C.; Hao, W. J.; Tu, S. J.; Jiang, B. Adv. Synth. Catal. 2021, 363, 5162.

DOI

(c) Wang, J. Y.; Li, C. L.; Xu, T.; Li, M. F.; Hao, W. J.; Tu, S. J.; Wang, J.; Li, G.; Yu, Z. X.; Jiang, B. Chin. J. Chem. 2022, 40, 1767.

DOI

(d) Miao, A. Q.; Wang, Y. X.; Xu, L. L.; Hao, W. J.; Tu, S. J.; Zhang, J. P.; Jiang, B. Green Synth. Catal. 2024, 5, 165.

(e) Liu, Z. L.; Wang, Y. X.; Yang, Z. Q.; Yang, Y. H.; Liu, Y. P.; Hao, W. J.; Jiang, B. Chem. Commun. 2024, 60, 8908

DOI

(f) Wang, Y. X.; Li, C. L.; Liu, Y. P.; Hao, W. J.; Yu, Z. X.; Jiang, B. J. Org. Chem. 2024, 89, 9381.

DOI

[15]
Deng, R.-X.; Han, T.-J.; Gao, X.; Yang, Y.-F.; ∙Mei, G.-J. iScience 2022, 25, 103913.

DOI

[16]
Feng, H.; Hu, H.; Zhao, J. Org. Lett. 2026, 28, 1821.

DOI

[17]
(a) Wang, H. X.; Yang, C.; Xue, B. Y.; Xie, M. S.; Tian, Y.; Peng, C.; Guo, H. M. Nat. Commun. 2023, 14, 2270.

DOI

(b) Yu, H. B.; Chen, Y. G.; Tian, Y.; Xie, M. S.; Guo, H. M. ACS Catal. 2024, 14, 8930.

DOI

(c) Wang, H. L.; Wei, T.; Bi, R. Y.; Xie, M. S.; Guo, H. M. Adv. Synth. Catal. 2024, 366, 3188.

DOI

(d) Hou, C. Y.; Yang, C.; Tian, Y.; Xie, M. S.; Guo, H. M. Org. Lett. 2024, 26, 6390.

DOI

[18]
(a) Ahreum, K.; Chanhee, L.; Jayoung, S.; Sang, K. L.; Yongseok, K. Nat. Commun. 2023, 14, 5502.

DOI PMID

(b) Ge, S. L.; Cao, W. D.; Kang, T. F.; Hu, B. W.; Zhang, H.; Su, Z. S.; Liu, X. H.; Feng, X. M. Angew. Chem., Int. Ed. 2019, 58, 4017.

DOI

(c) Dorine, B.; Louis, C. M.; Carmen, S.; Alexandra, M. Z. S.; Andrew, D. S. J. Am. Chem. Soc. 2011, 133, 2714.

DOI

(d) Xu, M. H.; Yuan, Y. H.; Liang, D. D.; Zhang, X. M.; Zhang, F. M.; Tu, Y. Q.; Ma, A. J.; Zhang, K.; Peng, J. B. Org. Chem. Front. 2021, 8, 3292.

DOI

文章导航

/